1. Home
  2. |Insights
  3. |What the Midterms Mean for Congressional Investigations

What the Midterms Mean for Congressional Investigations

Webinar | 11.05.26, 12:00 PM EST - 1:00 PM EST

Address

Virtual

The November 3 midterm elections will decide control of the U.S. Senate and House of Representatives. In turn, the outcome determines who controls committee investigative agendas–and subpoena authority–in the new Congress that will convene in January 2027. Join Crowell & Moring partners James P. Bair and Sharmi Das 48 hours after Election Day for a timely analysis of what the results mean for congressional oversight of companies, executives, and industries across sectors, including technology, government contracting, financial services, education, and health care.

In the run-up to the midterm elections, private companies are increasingly fielding congressional inquiries as members on both sides of the aisle look to advance their policy priorities in the current political landscape. Jamie and Sharmi will provide preliminary insights into the what we know – and what we may not know – following the November 3 midterm elections, and what those results mean for companies navigating this landscape.

Topics will include:
•  Key election outcomes and related developments
•  What the election results mean for committee gavels, chairs, and investigative priorities in both chambers
•  Investigative priorities across industry sectors, including bipartisan focus areas
•  What the composition of Congress could mean for the volume and direction of investigative activity

For more information, please visit these areas: Government Contracts , Government Contracts Investigations

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.